Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 1997, for Corniche Group Incorporated (noted as Lisata Therapeutics in metadata, but the filing text identifies Corniche Group). The Company has been inactive since February 1996, when its UK operating subsidiaries were placed in receivership due to liquidity issues and operating losses. Current activities are limited to settling liabilities and conducting private securities offerings to fund a potential future acquisition of an operating business.
Key Financial Metrics
| Metric | Q2 1997 | Q2 1996 |
|---|---|---|
| Net Sales | $0 | $0 |
| Operating Loss | $(120,816) | $(32,250) |
| Net Loss | $(138,686) | $(49,962) |
| Loss Per Share (Common) | $(0.04) | $(0.02) |
| Cash and Equivalents (End of Period) | $263,428 | $449 |
| Total Assets | $265,165 | N/A |
| Total Current Liabilities | $182,560 | N/A |
| Stockholders' Equity | $82,605 | N/A |
Liquidity: Cash increased significantly from $13,167 at March 31, 1997, to $263,428 at June 30, 1997, driven by financing activities. The Company has no operating cash flow.
Material Changes vs. Prior Period
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased by $88,566 year-over-year to $120,816. This increase is primarily attributed to $76,500 in costs associated with redeeming common stock purchase warrants and higher professional fees.
- Debt Reduction: Notes payable were reduced from $400,000 (March 31, 1997) to $0 (June 30, 1997) following the payment of promissory notes.
- Equity Position: Stockholders' equity improved from a deficiency of $(651,709) at March 31, 1997, to a positive balance of $82,605 at June 30, 1997, due to the issuance of common stock.
Outlook, Risks, and Management Commentary
Capital Raising: The Company commenced a private securities offering on May 15, 1997, selling units of common stock. Through June 30, 1997, 194 units were sold for gross proceeds of $970,000. Proceeds are being used for working capital, paying off notes, and redeeming warrants.
Future Operations: Management does not expect to generate operating revenues until the consummation of a business acquisition. There is no assurance that an acquisition will be completed or that it will result in material revenues.
Risks: The financial statements are prepared assuming a "going concern," but the Company's ability to continue depends entirely on obtaining outside financing and completing an acquisition. The Company has fully reserved tax benefits from net operating losses due to ownership change limitations.
Investor Verification Checklist
- Verify the status of the ongoing private securities offering and whether the target of $300,000 (prior offering) or $2,000,000 (current offering) has been met.
- Confirm the timeline and likelihood of a business acquisition, as the Company has no current revenue-generating operations.
- Review the terms of the remaining preferred stock dividends payable ($162,086) and their impact on future cash requirements.
- Assess the sustainability of the current cash balance ($263,428) against ongoing SG&A expenses of approximately $120,000 per quarter.